Polymeric nanoparticles of FMISO: are nano-radiopharmaceuticals better than conventional ones?
Nanotechnology has been the last frontier in the diagnoses and treatment of many diseases, especially in oncology. The use of nanoparticles of radiopharmaceuticals may represent the future of Nuclear Medicine. In this study we developed, characterized and tested polymeric nanoparticles of FMISO (fluoromisonidazole) in a dynamic study of biodistribution. The results of the development as characterization showed that nanoparticles were well obtained with a size range of 300- 500 nm and a spherical shape.
Laboratory of Nanoradiopharmaceuticals – Rio de Janeiro – Brazil.
Marta
M
de Souza Albernaz
Beatriz Ferreira
BF
de Carvalho Patricio
Gilberto
G
Weissmuller
Franceline
F
Reynaud
Tom Ch
TCh
Adamsen
Ralph
R
Santos-Oliveira
D018625:Microscopy, Atomic Force; D008920:Misonidazole / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000493:pharmacokinetics; D053758:Nanoparticles / Q000737:chemistry*; D011838:Radiation-Sensitizing Agents / Q000138:chemical synthesis / Q000493:pharmacokinetics*; D019275:Radiopharmaceuticals / Q000138:chemical synthesis / Q000493:pharmacokinetics*
D011838:Radiation-Sensitizing Agents; D019275:Radiopharmaceuticals; C031843:fluoromisonidazole; D008920:Misonidazole